Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Harrow, United Kingdom, HA1 3UJ
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy participants
- Participants of Japanese descent are defined as: First generation (born to 2 Japanese parents and 4 Japanese grandparents).
- Participants of Japanese descent must be between 20 and 55 years of age.
Exclusion Criteria:
- Current or recurrent disease
- Current or relevant history of physical or psychiatric illness.
- Any other significant disease or disorder that, in the opinion of the Investigator, may put the participant at risk.
- History of significant allergic reaction (eg, anaphylaxis or angioedema) to any product (eg, food, pharmaceutical).
- Female participants who are pregnant or breastfeeding.
- Major surgery or hospitalization within 90 days prior to dosing on Day1.
- History of exposure to asfotase alfa.
- History of allergy or hypersensitivity to excipients of asfotase alfa or ALXN1910 (eg,sodium phosphate, sodium chloride).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1
Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV.
|
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
|
|
Experimental: Cohort 2
Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
|
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
|
|
Experimental: Cohort 3
Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV.
|
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
|
|
Experimental: Cohort 4
Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC.
|
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
|
|
Experimental: Cohort 5
Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC.
|
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
|
|
Experimental: Cohort 6
Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC.
|
Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.
Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Time Frame: Day 1 (postdose) through Day 75
|
The safety and tolerability of ALXN1910 was assessed.
|
Day 1 (postdose) through Day 75
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Observed Serum Concentration (Cmax)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The Cmax was assessed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Time to Maximum Observed Serum Concentration (Tmax)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The Tmax was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Apparent Terminal Elimination Half Life (t1/2)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The t1/2 was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Terminal-phase Elimination Rate Constant (λz)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The λz was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
AUC From Time Zero to the Last Quantifiable Concentratio (AUCt)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The AUCt was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
AUC From Time Zero Extrapolated to Infinity (AUC∞)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The AUC∞ was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
AUC From Time Zero to 168h (AUC0-168)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The AUC0-168 was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Percentage of AUC∞ Obtained by Extrapolation Beyond Tlast (%AUCex)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The %AUCex was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Total Body Clearance (for IV Cohorts) or Apparent Clearance (for SC Cohorts) (CL or CL/F)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The CL or CL/F was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Volume of Distribution (for IV Cohorts) or Apparent Volume of Distribution (for SC Cohorts) (Vd or Vd/F)
Time Frame: Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
The Vd or Vd/F was assed as PK parameter of single ascending doses of ALXN1910.
|
Days 1 through 5 (predose and up to 96 hours postdose), postdose on Days 6, 7, 8, 15, 22, 29, 36, 43, and 75
|
|
Plasma Concentration of Inorganic Pyrophosphate (PPi)
Time Frame: Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
The plasma concentrations of PPi was assesed.
|
Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
|
Plasma Concentration of Pyridoxal (PL)
Time Frame: Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
The plasma concentrations of PL was assessed.
|
Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
|
Plasma Concentration of Pyridoxal 5-Phosphate (PLP)
Time Frame: Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
The plasma concentrations of PLP was assessed.
|
Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
|
Plasma Concentration of Pyridoxic Acid (PA)
Time Frame: Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
The plasma concentrations of PA was assessed.
|
Day 1 (predose), 2, 3, 5, 8, 15, 22, 29, 36, 43, and 75
|
|
Number of Participants With Positive Treatment-Emergent Antidrug Antibodies (ADAs)
Time Frame: Day 1 (postdose) through Day 75
|
The ADAs of ALXN1910 was assessed as immunogenicity parameter.
Treatment-emergent ADA Responses is defined as a positive result in the ADA assay post first dose, when baseline results are negative or missing.
|
Day 1 (postdose) through Day 75
|
|
Geometric Mean Ratio (GMR) of Area Under the Curve (AUC∞) Values of Subcutaneous (SC) Versus Intravenous (IV) Serum Concentration of ALXN1910
Time Frame: Up to Day 75
|
The absolute bioavailability GMR AUC∞ of ALXN1910 SC was assessed.
|
Up to Day 75
|
|
Maximum Observed Serum Concentration (Cmax) in Japanese and Non-Japanese Participants
Time Frame: Up to Day 75
|
Quantitative assessment of PK parameter (Cmax) was assessed between Japanese and non-Japanese participants.
|
Up to Day 75
|
|
AUC From Time Zero to the Last Quantifiable Concentration (AUCt) in Japanese and Non-Japanese Participants
Time Frame: Up to Day 75
|
Quantitative assessment of PK parameter (AUCt) was assessed between Japanese and non-Japanese participants.
|
Up to Day 75
|
|
AUC From Time Zero Extrapolated to Infinity (AUC∞) in Japanese and Non-Japanese Participants
Time Frame: Up to Day 75
|
Quantitative assessment of PK parameter (AUC∞) was assessed between Japanese and non-Japanese participants.
|
Up to Day 75
|
|
Change From Baseline in Inorganic Pyrophosphate Concentration in Japanese and Non-Japanese Participants
Time Frame: Day 2, 15, 22, 43, and 75
|
Change from baseline in PD parameter Inorganic Pyrophosphate was evaluated over time for Japanese and non-Japanese participants (Cohort 2 versus Cohort 4) on active treatment.
|
Day 2, 15, 22, 43, and 75
|
|
Change From Baseline in Pyridoxal-5-phosphate Concentration in Japanese and Non-Japanese Participants
Time Frame: Day 2, 15, 22, 43, and 75
|
Change from baseline in PD parameter Pyridoxal-5-phosphate was evaluated over time for Japanese and non-Japanese participants (Cohort 2 versus Cohort 4) on active treatment
|
Day 2, 15, 22, 43, and 75
|
|
Change From Baseline in Pyridoxal Concentration in Japanese and Non-Japanese Participants
Time Frame: Day 2, 15, 22, 43, and 75
|
Change from baseline in PD parameter Pyridoxal was evaluated over time for Japanese and non-Japanese participants (Cohort 2 versus Cohort 4) on active treatment.
|
Day 2, 15, 22, 43, and 75
|
|
Change From Baseline in Pyridoxic Acid Concentration in Japanese and Non-Japanese Participants
Time Frame: Day 2, 15, 22, 43, and 75
|
Change from baseline in PD parameter Pyridoxic Acid was evaluated over time for Japanese and non-Japanese participants (Cohort 2 versus Cohort 4) on active treatment.
|
Day 2, 15, 22, 43, and 75
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ALXN1910-HV-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.